Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial-Reference-Cited by-同舟云学术

Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

Published:2022-07 Issue:7 Volume:21 Page:597-607
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Ashina Messoud,Lanteri-Minet Michel,Pozo-Rosich Patricia,Ettrup Anders,Christoffersen Cecilie Laurberg,Josiassen Mette Krog,Phul Ravinder,Sperling Bjørn

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference33 articles.

1. Migraine;Ashina;N Engl J Med,2020

2. Migraine: epidemiology and systems of care;Ashina;Lancet,2021

3. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache;Steiner;J Headache Pain,2019

4. The American Headache Society Consensus Statement: update on integrating new migraine treatments into clinical practice;Ailani;Headache,2021

5. Canadian Headache Society guideline for migraine prophylaxis;Pringsheim;Can J Neurol Sci,2012

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine;Cephalalgia;2024-09

2. Algorithmus zur medikamentösen Migräneprophylaxe;Schmerzmedizin;2024-07

3. Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study;Brain Sciences;2024-06-30

4. Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications;Frontiers in Neurology;2024-06-13

5. Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies – insights from the German NeuroTransData registry;The Journal of Headache and Pain;2024-06-03